title: RESULTS OF PARS PLANA VITRECTOMY FOR THE MANAGEMENT OF ENDOGENOUS FUNGAL ENDOPHTHALMITIS AFTER URINARY TRACT PROCEDURES.
abstract: OBJECTIVE
  To report the results of pars plana vitrectomy with adjuvant intravitreal amphotericin B and systemic fluconazole in the management of endogenous endophthalmitis after the urinary tract procedures.
  
  
  METHODS
  Retrospective study of 10 eyes of 7 patients diagnosed as endogenous fungal endophthalmitis. Pars planavitrectomy with adjuvant intravitreal amphotericin B and oral fluconazole was conducted once the general condition is suitable. The final anatomical and functional results were evaluated.
  
  
  RESULTS
  Ten eyes of seven patients, five men and two women had pars plana vitrectomy. Control of infection was achieved in all cases. Visual acuity improved in 7 eyes (70%), remained the same in 2 eyes (20%), and worsened in 1 eye (10%). The retina was flat in all cases. No eye developed phthisis bulbi.
  
  
  CONCLUSIONS
  In cases of fungal endophthalmitis, after urinary tract procedures, the prevention of phthisis bulbi can be achieved in all cases. Improvement of vision can be achieved in most of the cases. The final visual status depends on visual acuity at presentation, macular affection, and the presence of retinal detachment at presentation.
authors.affiliation: *Tanta University, Tanta, Egypt; †Magrabi Eye Hospital, Tanta, Egypt; ‡Menoufia University, Menoufia, Egypt; §Damanhour Teaching Hospital, Damanhour, Egypt; ¶Al-Azhar University, Cairo, Egypt; and **Benha University, Benha, Egypt.
authors.forename: Hammouda H
authors.initials: HH
authors.lastname: Ghoraba
authors.forename: Amin F
authors.initials: AF
authors.lastname: Ellakwa
authors.forename: Emad M
authors.initials: EM
authors.lastname: Elgemai
authors.forename: Hosam O
authors.initials: HO
authors.lastname: Mansour
authors.forename: Mohammed A
authors.initials: MA
authors.lastname: Heikal
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D002175:Candida / Q000302:isolation & purification; D009877:Endophthalmitis / Q000188:drug therapy / Q000382:microbiology* / Q000601:surgery*; D015821:Eye Infections, Fungal / Q000382:microbiology* / Q000628:therapy; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy / Q000382:microbiology* / Q000601:surgery*; D012189:Retrospective Studies; D013520:Urologic Surgical Procedures / Q000009:adverse effects*; D014821:Vitrectomy / Q000379:methods
chemical_list: D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D000666:Amphotericin B; D015725:Fluconazole